Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
PathologyWatch›
Analysis
AddedFeb 27, 2023
UpdatedJul 21, 2026
PathologyWatch

PathologyWatch

An intuitive and easy-to-implement digital pathology solution for dermatologists and labs.

Founded
2017
Loading
Overview
Analysis
Compare
Fundraising
Employees

Contents

  1. 01Products & Services
  2. 02Competitive Strengths
  3. 03Competitive Risks
  4. 04Pricing Strategy
  1. 01Products & Services
  2. 02Competitive Strengths
  3. 03Competitive Risks
  4. 04Pricing Strategy

Product Overview

PathologyWatch is a computational pathology company that provides a digital pathology platform for clinical laboratories and healthcare providers. The company's platform is designed to improve the accuracy and efficiency of pathology diagnoses by leveraging advanced digital technologies, including artificial intelligence (AI) and machine learning (ML).

PathologyWatch's product includes several key features, including:

Digital Pathology Image Management: The platform enables the digitization and management of pathology images, allowing healthcare providers to easily access and share images for diagnosis and consultation.

AI-powered Diagnosis Assistance: AI-powered algorithms provide automated assistance to pathologists in the diagnosis process, helping to improve the accuracy and efficiency of diagnoses.

Remote Consultation: The platform allows for remote consultation between pathologists, enabling collaboration and knowledge-sharing between experts regardless of their location.

Quality Assurance and Compliance: Several features ensure quality assurance and compliance with regulatory requirements, including documentation and reporting.

Overall, PathologyWatch's product is designed to improve the accuracy and efficiency of pathology diagnoses by leveraging advanced digital technologies. The platform enables healthcare providers to digitize and manage pathology images, provides AI-powered diagnosis assistance, enables remote consultation, and ensures quality assurance and compliance with regulatory requirements.

Competitive Advantages

PathologyWatch has several competitive advantages that set it apart from other companies in the computational pathology market. These advantages include:

AI-Powered Diagnosis Assistance: The company’s platform leverages advanced AI and machine learning algorithms to provide diagnosis assistance to pathologists. This technology helps to improve the accuracy and efficiency of diagnoses, and allows pathologists to provide more accurate and timely results to healthcare providers and patients.

Remote Consultation: PathologyWatch enables remote consultation between pathologists, allowing for collaboration and knowledge-sharing between experts regardless of their location. This feature helps to improve the accuracy and efficiency of diagnoses and ensures that patients receive the best possible care.

Compliance and Quality Assurance: Several integrated features validate compliance with regulatory requirements and quality assurance standards. This helps to ensure that diagnoses are accurate and that patient data is protected.

Experienced Leadership: PathologyWatch's leadership team has extensive experience in the pathology and healthcare technology industries, which helps the company to stay ahead of industry trends and develop innovative solutions.

Customer Service and Support: The company is committed to providing excellent customer service and support, with a dedicated team of professionals available to assist customers with any questions or issues that may arise.

Overall, PathologyWatch's competitive advantages are centered around its advanced technology, commitment to compliance and quality assurance, experienced leadership, and dedication to customer service and support. These advantages position the company for continued growth and success in the computational pathology market.

Competitive Disadvantages

One potential competitive disadvantage for PathologyWatch is the fact that the computational pathology market is relatively new and still developing. While the adoption of these advanced tools are increasing, some healthcare providers may be hesitant to adopt new technology due to concerns about cost, implementation, and potential disruptions to existing workflows.

Additionally, there are several well-established companies in the computational pathology space that PathologyWatch must compete with. These companies have larger customer bases and more resources, which can make it challenging for PathologyWatch to gain market share and compete on pricing.

Another potential disadvantage is the fact that some healthcare providers may be hesitant to trust AI and machine learning algorithms for diagnosis assistance. While these technologies have shown promise in improving accuracy and efficiency, some providers may be concerned about the potential for errors or bias in the algorithms.

Finally, as with any healthcare technology company, PathologyWatch must navigate a complex regulatory landscape. Compliance with regulatory requirements can be challenging and time-consuming, and failure to comply can result in significant fines and legal penalties.

Overall, while PathologyWatch has several competitive advantages, there are also potential disadvantages that the company must navigate in order to successfully grow and compete in the digital pathology and healthcare technology markets.

Pricing Strategy

PathologyWatch's pricing strategy is based on a per-case model, which means that customers are charged a fee for each pathology case that is processed through the platform. The exact pricing varies depending on the volume of cases and the specific needs of the customer.

PathologyWatch offers flexible pricing options to accommodate the needs of different types of customers, including clinical laboratories, pathology groups, and healthcare providers. The company also offers customized pricing for customers with unique requirements.

Additionally, PathologyWatch offers a range of pricing options to suit different budget constraints. Customers can choose between a flat fee per case or a tiered pricing model that provides discounts based on the volume of cases processed.

Overall, PathologyWatch's pricing strategy is designed to provide flexibility and affordability to customers while also ensuring that the company can generate revenue based on the volume of cases processed through the platform.